Ann Hynes

Charles Rhyee

Eric Coldwell

Jailendra Singh

Justin Bowers

Max Smock

Daniel Leonard

David Windley

Michael Cherny

Dave Windley

Kyle Crews

Luke Sergott

- Medpace Holdings, Inc. reported **Q3 2025 revenue of $659.9 million**, a **23.7% increase** from the prior-year period, with **GAAP net income of $111.1 million** and **$3.86 per diluted share**.  **[1668397_411e4cea878d4cc0bf0ba27f6fb46357_0]** 
- **Net new business awards** for Q3 2025 increased **47.9%** year-over-year to **$789.6 million**, resulting in a **net book-to-bill ratio of 1.20x**.  **[1668397_411e4cea878d4cc0bf0ba27f6fb46357_0]** 
- The company's **backlog** as of September 30, 2025, grew **2.5%** to **$3,000.6 million**.  **[1668397_411e4cea878d4cc0bf0ba27f6fb46357_0]** 
- Medpace forecasts **full year 2025 revenue** between **$2.480 billion and $2.530 billion** and **diluted earnings per share** in the range of **$14.60 to $14.86**.  **[1668397_411e4cea878d4cc0bf0ba27f6fb46357_1]** 
- For the nine months ended September 30, 2025, the company repurchased **2,961,924 shares** for a total of **$912.9 million**.  **[1668397_411e4cea878d4cc0bf0ba27f6fb46357_1]**

Medpace Holdings, Inc. Announces Third Quarter 2025 Results and Full Year Guidance

Medpace Holdings (MEDP)